Patents by Inventor Guifen Zhang

Guifen Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isofuranone compounds useful as HPK1 inhibitors
    Patent number: 11166959
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Erika M. V. Araujo, Yan Chen, Bireshwar Dasgupta, Andrew P. Degnan, Matthew D. Hill, Godwin Kwame Kumi, Harold A. Mastalerz, Mark D. Wittman, Bradley C. Pearce, Guifen Zhang
  • ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS
    Publication number: 20200390776
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 5, 2018
    Publication date: December 17, 2020
    Inventors: Erika M.V. Araujo, Yan Chen, Bireshwar Dasgupta, Andrew P. Degnan, Matthew D. Hill, Godwin Kwame Kumi, Harold A. Mastalerz, Mark D. Wittman, Bradley C. Pearce, Guifen Zhang
  • HDAC6 selective inhibitors, preparation method therefor, and application thereof
    Patent number: 10745389
    Abstract: Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: August 18, 2020
    Assignees: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD, CSTONE PHARMACEUTICALS
    Inventors: Hao Wu, Changqing Wei, Qiang Guo, Guifen Zhang, Bin Liu, Yonggang Liao, Yao Xiao, Shuhui Chen
  • HDAC6 Selective Inhibitors, Preparation Method Therefor, and Application Thereof
    Publication number: 20190375735
    Abstract: Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: December 12, 2019
    Inventors: Hao Wu, Changqing Wei, Qiang Guo, Guifen Zhang, Bin Liu, Yonggang Liao, Yao Xiao, Shuhui Chen
  • Imidazotriazinecarbonitriles useful as kinase inhibitors
    Patent number: 9556178
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Ashvinikumar V. Gavai, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann
  • IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20160108050
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer lnghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann, Yong Zhang, Libing Chen, Bin Chen, John S. Tokarski, Ashvinikumar V. Gavai
  • Imidazotriazinecarbonitriles useful as kinase inhibitors
    Patent number: 9273057
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann, Yong Zhang, Libing Chen, Bin Chen, John S. Tokarski, Ashvinikumar V. Gavai
  • IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20150210697
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 30, 2015
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann, Yong Zhang, Libing Chen, Bin Chen, John S. Tokarski, Ashvinikumar V. Gavai
  • IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20150065465
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: November 4, 2014
    Publication date: March 5, 2015
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Ashvinikumar V. Gavai, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann
  • Imidazotriazinecarbonitriles useful as kinase inhibitors
    Patent number: 8940736
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 27, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Ashvinikumar V. Gavai, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann
  • IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20140018319
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 16, 2014
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Ashvinikumar V. Gavai, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8592579
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: November 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20120302747
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: August 7, 2012
    Publication date: November 29, 2012
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20110124623
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7879855
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: February 1, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
    Patent number: 7619083
    Abstract: The invention relates to 2,4-dichloropyrrolo[1,2-f][1,2,4]triazines, which are intermediates useful in preparing at least one 2,4-disubstituted pyrrolotriazine compound, and at least one method for making such intermediates.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: November 17, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Guifen Zhang
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20090239838
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: March 26, 2009
    Publication date: September 24, 2009
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7534792
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20080009497
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 10, 2008
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
    Patent number: 7232901
    Abstract: Described herein is at least one pyrrolo[1,2-f][1,2,4]triazine-2,4(1H,3H)-dione, which is an intermediates useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and at least one method for making such intermediate.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Guifen Zhang